AstraZeneca Signs Licensing Deal with China’s BioKangtai for 100 Million Doses of Oxford COVID-19 Vaccine by Year End

AstraZeneca (Cambridgeshire, England) has signed a licensing deal with Chinese firm BioKangtai (Guangdong, Chin) to supply its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK), to China.

AstraZeneca announced the deal in a Chinese social media post and also stated that both the companies would explore the possibility of producing the vaccine for other markets as well, according to a FiercePharma report.

BioKangtai, a Chinese vaccine company, already produces a recombinant hepatitis B vaccine (Saccharomyces cerevisiae), an influenza type b conjugate vaccine and vaccines for measles and rubella. More...